47 related articles for article (PubMed ID: 24284973)
1. Mammalian orthoreovirus can exit cells in extracellular vesicles.
Smith SC; Krystofiak E; Ogden KM
bioRxiv; 2023 Aug; ():. PubMed ID: 37693509
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic Viruses for Canine Cancer Treatment.
Sánchez D; Cesarman-Maus G; Amador-Molina A; Lizano M
Cancers (Basel); 2018 Oct; 10(11):. PubMed ID: 30373251
[TBL] [Abstract][Full Text] [Related]
3. Seroepidemiology of reovirus in healthy dogs in six prefectures in Japan.
Hwang CC; Mochizuki M; Maeda K; Okuda M; Mizuno T
J Vet Med Sci; 2014 Mar; 76(3):471-5. PubMed ID: 24284973
[TBL] [Abstract][Full Text] [Related]
4. Serological epidemiology of reovirus infection. 1.
Fukumi H; Takeuchi Y; Ishida M; Saito H
Jpn J Med Sci Biol; 1969 Feb; 22(1):13-21. PubMed ID: 4309509
[No Abstract] [Full Text] [Related]
5. Polymorphisms in the Most Oncolytic Reovirus Strain Confer Enhanced Cell Attachment, Transcription, and Single-Step Replication Kinetics.
Mohamed A; Smiley JR; Shmulevitz M
J Virol; 2020 Jan; 94(4):. PubMed ID: 31776267
[TBL] [Abstract][Full Text] [Related]
6. Oncolytic reovirus therapy: Pilot study in dogs with spontaneously occurring tumours.
Hwang CC; Igase M; Sakurai M; Haraguchi T; Tani K; Itamoto K; Shimokawa T; Nakaichi M; Nemoto Y; Noguchi S; Coffey M; Okuda M; Mizuno T
Vet Comp Oncol; 2018 Jun; 16(2):229-238. PubMed ID: 29076241
[TBL] [Abstract][Full Text] [Related]
7. Reovirus antibody patterns in dogs: a trial for the application of principal component analysis to seroepidemiology.
Murakami T; Kato H
Natl Inst Anim Health Q (Tokyo); 1975; 15(1):8-14. PubMed ID: 164634
[TBL] [Abstract][Full Text] [Related]
8. Single Amino Acid Differences between Closely Related Reovirus T3D Lab Strains Alter Oncolytic Potency
Mohamed A; Clements DR; Gujar SA; Lee PW; Smiley JR; Shmulevitz M
J Virol; 2020 Jan; 94(4):. PubMed ID: 31748391
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic reovirus in canine mast cell tumor.
Hwang CC; Umeki S; Kubo M; Hayashi T; Shimoda H; Mochizuki M; Maeda K; Baba K; Hiraoka H; Coffey M; Okuda M; Mizuno T
PLoS One; 2013; 8(9):e73555. PubMed ID: 24073198
[TBL] [Abstract][Full Text] [Related]
10. Reovirus: a targeted therapeutic--progress and potential.
Maitra R; Ghalib MH; Goel S
Mol Cancer Res; 2012 Dec; 10(12):1514-25. PubMed ID: 23038811
[TBL] [Abstract][Full Text] [Related]
11. Novel human reovirus isolated from children with acute necrotizing encephalopathy.
Ouattara LA; Barin F; Barthez MA; Bonnaud B; Roingeard P; Goudeau A; Castelnau P; Vernet G; Paranhos-Baccalà G; Komurian-Pradel F
Emerg Infect Dis; 2011 Aug; 17(8):1436-44. PubMed ID: 21801621
[TBL] [Abstract][Full Text] [Related]
12. Mammalian reoviruses: propagation, quantification, and storage.
Berard A; Coombs KM
Curr Protoc Microbiol; 2009 Aug; Chapter 15():Unit15C.1. PubMed ID: 19653214
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial.
White CL; Twigger KR; Vidal L; De Bono JS; Coffey M; Heinemann L; Morgan R; Merrick A; Errington F; Vile RG; Melcher AA; Pandha HS; Harrington KJ
Gene Ther; 2008 Jun; 15(12):911-20. PubMed ID: 18323793
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
